<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:npr="https://www.npr.org/rss/" xmlns:nprml="https://api.npr.org/nprml" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:media="http://search.yahoo.com/mrss/" version="2.0">
  <channel>
    <title>NPR: Ranbaxy</title>
    <link>https://www.npr.org/templates/story/story.php?storyId=722222763</link>
    <description>Ranbaxy</description>
    <language>en</language>
    <copyright>Copyright 2024 NPR - For Personal Use Only</copyright>
    <generator>Story API Shim 1.2.24</generator>
    <lastBuildDate>Sun, 05 Apr 2026 12:50:16 -0400</lastBuildDate>
    <image>
      <url>https://media.npr.org/images/podcasts/primary/npr_generic_image_300.jpg?s=200</url>
      <title>NPR: Ranbaxy</title>
      <link>https://www.npr.org/tags/722222763/ranbaxy</link>
    </image>
    <item>
      <title>&apos;Bottle Of Lies&apos; Exposes The Dark Side Of The Generic-Drug Boom</title>
      <description>A new book investigates the history of unsafe and deceptive practices by some generic-drug manufacturers, and explains why U.S. regulators struggle to keep up with a global industry.</description>
      <pubDate>Sun, 12 May 2019 12:52:00 -0400</pubDate>
      <link>https://www.npr.org/sections/health-shots/2019/05/12/722216512/bottle-of-lies-exposes-the-dark-side-of-the-generic-drug-boom</link>
      <guid>https://www.npr.org/sections/health-shots/2019/05/12/722216512/bottle-of-lies-exposes-the-dark-side-of-the-generic-drug-boom</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2019/05/10/gettyimages-477058103-3e4c615cb2920fcfe4c444ba4bccd3445a14558e.jpg' alt='An FDA inspection of this Ranbaxy facility in Toansa, Punjab, India, in 2014, revealed drug quality testing violations, resulting in the FDA prohibiting Ranbaxy from marketing drugs in the U.S. that were manufactured at this plant.'/><p>A new book investigates the history of unsafe and deceptive practices by some generic-drug manufacturers, and explains why U.S. regulators struggle to keep up with a global industry.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=722216512' />]]></content:encoded>
      <dc:creator>Jonathan Lambert</dc:creator>
    </item>
  </channel>
</rss>